BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Stock Short Interest Report for September

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) was the target of a large growth in short interest in September. As of September 30th, there was short interest totaling 473,807 shares, a growth of 244.4% from the September 15th total of 137,567 shares. Based on an average daily trading volume, of 291,746 shares, the short-interest ratio is currently 1.6 days. Currently, 1.5% of the shares of the stock are short sold.

BlossomHill Therapeutics Trading Up 3.6%

Shares of BLSM traded up $0.60 during midday trading on Friday, hitting $17.48. The stock had a trading volume of 131,829 shares, compared to its average volume of 249,355. BlossomHill Therapeutics has a 1 year low of $15.25 and a 1 year high of $27.99. The stock has a market capitalization of $555.51 million and a price-to-earnings ratio of -2.00. The company’s 50 day moving average is $19.64.

BlossomHill Therapeutics (NASDAQ:BLSM) last released its earnings results on Friday, September 18th. The company reported ($8.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($7.91). As a group, sell-side analysts predict that BlossomHill Therapeutics will post -5.54 earnings per share for the current year.

Insider Transactions at BlossomHill Therapeutics

In other BlossomHill Therapeutics news, Director Orbimed Advisors Llc bought 625,000 shares of BlossomHill Therapeutics stock in a transaction dated Monday, August 10th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $10,000,000.00. Following the acquisition, the director directly owned 2,714,279 shares in the company, valued at approximately $43,428,464. This represents a 29.91% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Carl Gordon bought 625,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the transaction, the director directly owned 2,714,279 shares in the company, valued at approximately $43,428,464. This represents a 29.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders purchased 1,573,900 shares of company stock worth $25,181,900.

Analysts Set New Price Targets

A number of brokerages have issued reports on BLSM. JPMorgan Chase & Co. initiated coverage on BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an “overweight” rating and a $28.00 price objective on the stock. Lifesci Capital began coverage on BlossomHill Therapeutics in a report on Tuesday, September 1st. They issued an “outperform” rating and a $32.00 target price for the company. Zacks Research upgraded BlossomHill Therapeutics to a “hold” rating in a report on Wednesday, September 2nd. Wall Street Zen downgraded BlossomHill Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 3rd. Finally, Guggenheim increased their price target on BlossomHill Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a report on Monday, September 21st. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, BlossomHill Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.